◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: medium Compound SKIP-FOR-NOW HIGH

Turinabol

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW HIGH

"Same-family logic to all anabolic-androgenic steroids skip-at-20 cluster, with three turinabol-specific aggravators that make the verdict harder than for typical AAS in this user's archetype. (1) For a 20yo MMA athlete with peak endogenous testosterone (~600-900 ng/dL typical), no documented hypogonadism, and brain-priority + longevity orientation, the standard AAS risk constellation applies — HPG suppression with potential post-cycle anhedonia / mood crash, atherogenic dyslipidemia (turinabol crashes HDL particularly hard among AAS — non-aromatizable + DHT-pattern + 17α-alkylated triple-whammy), obligate hepatotoxicity via 17α-alkylation, modest body-comp upside achievable through training + nutrition + creatine alone. (2) Turinabol-specific: the M3 long-term metabolite (~20βOH-NorDHCMT) is detectable in urine up to 9-12+ months post-use via Sobolevsky-Rodchenkov 2012 LC-MS/MS, and the 2016 reanalyses of Beijing 2008 + London 2012 samples produced ~80 retroactive AAFs with cascading medal stripping. For ANY plausible competitive future (state amateur MMA, USADA-tested promotion, pro card path), CDMT is uniquely catastrophic — even years-old use is detectable. (3) Historical/safety-data weight: the East German State Plan Topic 14.25 (1968-1989) administered turinabol to ~10,000 athletes, many adolescent female swimmers/throwers/runners, producing a documented epidemic of virilization, liver tumors, cardiovascular disease, infertility, gynecological pathology, and offspring deformities (Franke + Berendonk 1997 Clinical Chemistry). It is one of the most thoroughly documented \"what happens when adolescents are given an AAS for years\" datasets in medicine, and the answer is \"long-term harm.\" Verdict reverses ONLY for documented severe catabolic medical indication under endocrinology supervision — clinically implausible and turinabol is no longer manufactured anyway."

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload, MMA athlete with peak endogenous T (this user's archetype)
    SKIP-AT-

    HIGH confidence. Same-family logic to the entire AAS cluster + two turinabol-specific aggravators. (1) No documented hypogonadism, peak natural testosterone (typical 600-900 ng/dL at 20yo), no body-comp gap that justifies HPG suppression + atherogenic dyslipidemia + hepatotoxicity. Brain-priority framing makes mood-crash post-cycle and chronic CVD risk unjustifiable. (2) M3 long-term metabolite (~9-12 months urine detection) is uniquely catastrophic for any plausible future tested-MMA pathway — even years-old cycles stripped 2008/2012 Olympic medals retroactively in the 2016 reanalysis. (3) East German State Plan Topic 14.25 cohort (~10,000 athletes, many adolescents) provides one of medicine's most explicit "AAS in young athletes for sustained periods = long-term physical / hormonal / oncologic / psychiatric harm" datasets — the long-term-harm case is as well-documented as any AAS gets. The "lean dry gains" framing of turinabol does not change the underlying inappropriateness for the user.

  • 20-30 with documented severe catabolic indication (HIV wasting, severe trauma, post-surgical wasting)
    APPROPRIATE

    Rx alternatives exist (e.g., oxandrolone for FDA-approved indications) — turinabol itself is no longer manufactured, so this is a moot path.

  • 30-50, executive maintenance with documented hypogonadism
    SKIP

    TRT (injectable testosterone enanthate / cypionate) is the appropriate intervention, not oral 17α-alkylated AAS. Turinabol has no place in HRT protocols.

  • 50+, mild cognitive decline
    SKIP

    no indication; cardiovascular risk + lipid changes + hepatic burden outweigh marginal body comp gains.

  • Anxiety-prone
    SKIP

    mood lability + post-cycle crash + libido changes amplify anxiety burden.

  • High athletic load, tested status (NCAA, USADA, WADA, professional combat sport)
    SKIP-PERMANENT

    S1.1 banned; M3 metabolite uniquely catastrophic with 9-12+ month detection window; 2016 retroactive reanalysis demonstrated 8-year-old cycles get caught.

  • High athletic load, untested status
    SKIP

    as default for users in this archetype-archetype. The risk profile (HPG suppression, atherogenic dyslipidemia, hepatotoxicity, mood crash) is independent of testing status. For the user specifically, brain-priority + longevity + age-20 + ANY plausible future tested-MMA trajectory all converge on SKIP-AT-20. A 20yo MMA athlete who isn't currently tested may very well be tested 2-5 years from now if they progress through state amateur → USADA-tested promotions / pro card path; the M3 long-detection window means pre-pro-card use can disqualify the entire pro-MMA pathway.

  • Sleep-disordered
    SKIP

    Address sleep first; turinabol has no role and may modestly disturb sleep.

  • Recovery-focused (post-injury, post-illness, healthy young)
    SKIP

    for healthy young. For specific catabolic states, oxandrolone or injectable testosterone are appropriate Rx options under medical supervision (turinabol is no longer manufactured so isn't even on the menu).

  • Strength/anabolic-focused, healthy young eugonadal
    SKIP

    for users in this archetype-archetype specifically. The "lean dry gains" framing is real but does not make the compound appropriate for healthy 20yo with peak natural T.

  • Female athletes / fitness competitors
    T

    historically used by women in low doses (5-10 mg/day) due to non-aromatizing + relatively favorable anabolic-to-androgenic ratio; the East German adolescent female cohort documents irreversible virilization, voice deepening, hirsutism, clitoral hypertrophy at sustained low-dose exposure — this is not a "safe for women" AAS, it's a "less harsh than testosterone for women" AAS that still produced epidemic-level harms in the GDR cohort. Verdict: SKIP unless competitive bodybuilding context with explicit informed consent and time-limited very-low-dose protocols.

▸ Subjective experience (deep)

At bodybuilder doses (20-50 mg/day for 6 weeks)

  • Week 1-2: Subtle initial effects; less acute "kick" than dianabol (which has water-driven scale gains in days). Mild libido bump, slight pump improvement, modest strength gain.
  • Week 2-4: Onset of "fuller" muscle appearance with dry / hard / lean look (no water retention vs. aromatizing AAS); strength gains in the gym become noticeable; lean mass gain of 2-4 lb in trained males.
  • Week 4-6: Peak effects — typically 4-8 lb total lean mass gain in trained males, noticeable fat reduction with calorie deficit, pronounced vascularity, "harder" aesthetic. Mild libido shifts (often increased early, decreased later as HPG suppression takes hold). Mood: typically neutral or mildly positive; sometimes mild irritability. Sleep: usually unaffected.
  • Week 6+: Tapering of subjective novelty as receptor effects plateau; lipids deteriorating measurably on bloodwork; libido often noticeably lower as endogenous T crashes; mild anhedonia in some users. Bodybuilding convention is to stop at 6 weeks for liver-burden management.
  • Post-cycle: Without PCT, multi-week to multi-month low-libido / mood-low / fatigue period as HPG axis recovers. Strength and lean mass losses partially reverse as endogenous T returns.

Typical reported "characteristic effects"

  • Dry, hard, lean aesthetic — the signature look (similar to oxandrolone, distinct from dianabol's puffy/watery appearance)
  • No bloating / water retention (vs. test, dbol, anadrol)
  • Modest strength gains (less than test/tren/oxymetholone, comparable to oxandrolone)
  • Subjectively "smooth" — fewer mood swings, less aggression than test or tren
  • Lipid panel changes obvious on bloodwork (HDL crash is the universal report among health-conscious users — turinabol is among the worst AAS for lipid profile)
  • Forearm / bicep "pumps" sometimes uncomfortable / cramping (transient, typical of non-aromatizing AAS)
  • Mild liver tenderness possible at week 3-4 in susceptible users; transaminase elevation on labs
▸ Tolerance + cycling deep dive
  • Tolerance buildup: AR receptor downregulation reported with chronic exposure; functional tolerance to anabolic effects develops over weeks-months. Standard bodybuilder convention is 6-week cycles to avoid plateau and limit hepatic + HPG burden.
  • Recommended cycle (bodybuilder convention): 6 weeks on, equal off. Convention only — no clinical trial backing for healthy-adult body comp use. Liver burden escalates rapidly past 6 weeks.
  • Reset protocol: Off-cycle 12 weeks minimum; PCT (clomid + nolvadex, or enclomiphene) typically starts 1 week post-cycle and runs 4-6 weeks. HPG axis recovery is generally moderate-paced — slower than oxandrolone, faster than long-acting injectables.
▸ Stacking deep dive

Synergistic with (in bodybuilder protocols, NOT recommended for users in this archetype)

  • testosterone-enanthate (or other testosterone esters): Standard "test base" cycle adds turinabol for cutting / aesthetic enhancement; test prevents the worst HPG crash + libido loss
  • primobolan / methenolone: Dry-cycle pairing; both non-aromatizing; compounds liver burden if oral primobolan acetate is used
  • oxandrolone / anavar: Compounded "dry oral cut" stack; substantially compounds liver burden; rarely advised by experienced users
  • Clenbuterol / T3: Common cutting stack additions; compound cardiovascular load
  • GH / IGF-1: Adds anabolic synergy; compounds cancer / cardiomyopathy / hypoglycemia risks

Avoid stacking with

  • dianabol / methandienone: Pharmacological siblings (turinabol IS chlorinated dianabol); stacking provides no synergistic benefit and dramatically compounds liver burden — among the worst possible oral combinations
  • Other 17α-alkylated orals (methyltestosterone, fluoxymesterone, stanozolol, oxymetholone): Compounds hepatotoxicity dramatically; "oral stacking" widely cautioned against
  • anastrozole: Pharmacologically pointless for turinabol (non-aromatizing — no estradiol to suppress); adding an AI may further crash an already-low E2 and worsen lipids / mood / joint health
  • Hepatotoxic medications (acetaminophen at chronic doses, methotrexate, isoniazid): Additive liver burden
  • Statins: Pharmacologically logical for AAS users with crashing lipids, but adds hepatic burden — careful monitoring required
  • Insulin / oral hypoglycemics: No direct contraindication but monitor glucose given AAS effects on insulin sensitivity

Hepatic-support overlay (bodybuilder convention; not protective enough to make turinabol "safe")

  • tudca: Tauroursodeoxycholic acid 250-500 mg 2-3× daily during cycle. Reduces cholestatic / transaminitis risk by ~30-50% in observational AAS bodybuilder bloodwork series. Real but modest effect — does NOT make turinabol "safe" or eliminate the obligate 17α-alkylated hepatic burden, just reduces it. Standard bodybuilder addition for any 17αAA cycle.
  • NAC, milk thistle, S-adenosylmethionine: Lower-grade hepatic-support adjuncts; mechanism-plausible, evidence weaker than TUDCA.

Neutral / safe co-administration

  • Most non-hormonal nootropics (modafinil, citicoline, NAC, magnesium, fish oil — the user's V stack) — no direct interaction; the issue is not pharmacological collision but the underlying inappropriateness of AAS use in healthy young eugonadal males.
▸ Drug interactions deep dive
  • Warfarin / anticoagulants: Like other AAS, turinabol potentiates warfarin effect — dose reduction required, frequent INR monitoring
  • Insulin and oral hypoglycemics: Modest insulin sensitivity changes possible; monitor glucose in diabetic patients
  • Hepatotoxic medications: Additive — avoid concurrent acetaminophen at chronic high doses, methotrexate, isoniazid
  • CYP-mediated metabolism: Turinabol is hepatically metabolized via CYP3A4 + CYP11A1/B1/B2 (Schiffer 2016 PMID 26658226); strong CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit) may modestly elevate exposure and prolong detection
  • Detection (WADA short-term): ~7-14 days for parent + early metabolites
  • Detection (WADA long-term): ~9-12+ months for M3 long-term metabolite via LC-MS/MS
▸ Pharmacogenomics
  • CYP3A4 polymorphisms affect turinabol clearance modestly but no clinical pharmacogenomic dosing guidance exists
  • CYP11A1, CYP11B1, CYP11B2 variants (Schiffer 2016 — these enzymes participate in turinabol Phase I metabolism and are inhibited by it) affect metabolite formation patterns; clinically relevant only in altering the M3 detection profile (some individuals may show longer or shorter M3 windows)
  • AR (androgen receptor) CAG repeat length affects AR sensitivity and varies by ethnicity; shorter repeats = more sensitive AR = stronger response per dose. Not clinically actionable for AAS dosing decisions but explains some inter-individual variability.
  • Practical note: The user's 23andMe results (~June 2026) may include relevant SNPs but interpretation will not change the SKIP-AT-20 verdict.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Pharmaceutical (legitimate) No legitimate manufacturer exists — Jenapharm discontinued production in 1994 after privatization N/A N/A Genuine pharmaceutical-grade Oral-Turinabol from East Germany has not been manufactured for ~30 years; any blister claiming "Jenapharm" or "Oral-Turinabol" branding today is virtually certainly counterfeit
Underground lab (UGL) Common offerings on bodybuilding forums, telegram channels, dark markets $40-100/month at bodybuilder doses Low-to-medium Frequently underdosed or counterfeit (substituted with cheaper dianabol, methyltestosterone, methandienone, or simply mis-dosed); COA verification rarely available; quality varies dramatically
International / gray-market Limited Eastern European or Asian pharmaceutical-claim products $60-150/month Low Authenticity hard to verify; legal exposure varies; no reliable manufacturer chain

For users in this archetype: Sourcing is exceptionally poor — turinabol is among the most-counterfeited AAS due to the historical mystique + lack of legitimate manufacturer + relatively niche bodybuilder use case. Sourcing is not the gating question — appropriateness is. Skip the compound, do not engage the sourcing question.

▸ Biomarkers to track (deep)
  • Baseline (before starting): Total + free testosterone, SHBG, LH, FSH, E2 (sensitive assay), DHT, prolactin, full lipid panel (LDL, HDL, total cholesterol, triglycerides, ApoB, ideally Lp(a)), ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin, CBC (hematocrit), HbA1c, fasting glucose, eGFR, blood pressure, semen analysis (if fertility-relevant), echocardiogram if multi-cycle intent
  • During use (week 3-4): ALT, AST, GGT, full lipid panel, blood pressure, hematocrit. Flag if ALT >3× ULN, HDL drops >50%, BP >140/90.
  • End of cycle (week 6): Full HPG panel (T, LH, FSH, E2, DHT) to quantify suppression; lipids; LFTs
  • Post-cycle (week 4-8 post-cessation): HPG recovery check; lipid recovery; LFT normalization
  • Long-term (multi-cycle users): Annual lipid trends, periodic echocardiogram, liver imaging if any symptom or persistent transaminase elevation, formal CVD risk recalculation
  • Forensic-grade detection (turinabol-specific): M3 metabolite (~20βOH-NorDHCMT) detectable in urine ~9-12+ months post-use via WADA-accredited LC-MS/MS labs. For any future tested-competition aspiration, plan accordingly — a 2-year clean window post-last-dose is a reasonable margin given the documented long-term metabolite physiology.
▸ Controversies / open debates Live debate

1. The M3 metabolite + 2016 IOC reanalysis: science, politics, and the limits of retrospective testing

The 2012 Sobolevsky-Rodchenkov paper (J Steroid Biochem Mol Biol, PMID 22142641) identified six new long-term turinabol metabolites in human urine using LC-MS/MS. Among them, M3 (4α-chloro-17β-hydroxymethyl-17α-methyl-18-nor-5α-androstan-13-en-3α-ol, also written as ~20βOH-NorDHCMT) had the longest detection window — up to 45 days from a single 5 mg dose, and 9-12+ months in real-world chronic-use cohorts. The method was rapidly adopted by WADA-accredited labs.

The 2016 IOC reanalysis program retested stored urine samples from Beijing 2008 + London 2012 using the new M3 method. Approximately 80 adverse analytical findings for turinabol resulted, with cascading retroactive medal stripping. Athletes from Russia, Belarus, Ukraine, and Kazakhstan (weightlifters, throwers, wrestlers) were hit hardest. The retests revealed both legacy state-program-style doping (especially Russia) and individual chronic users.

The political controversy: Grigory Rodchenkov, who developed the M3 method while running the Moscow antidoping lab, later defected and admitted complicity in the Russian state doping program (subsequently the subject of the 2017 Oscar-winning documentary "Icarus"). Some scientists, particularly those connected to athletes who tested positive in 2016, have argued that the M3 method has reproducibility / specificity issues and that a fraction of the 2016 AAFs may represent false positives or contamination. The mainstream WADA + sports-integrity consensus is that the method is sound. A minority opposing view exists but has not been adopted by CAS in the cases brought.

Bottom line for the user: Whatever one thinks of the political controversy, the M3 method is the operational standard at WADA-accredited labs and produces real-world AAFs from years-old urine. Anyone planning a competitive future in tested combat sport (MMA / wrestling / BJJ-pro) should treat turinabol as essentially non-clearable on relevant timescales.

2. "Cleaner than dianabol" — partially true, partially overstated

Claim: Turinabol is cleaner / safer / milder than dianabol because it doesn't aromatize.

Reality:

  • Cleaner on water retention + gyno: True. The 4-chloro substitution blocks aromatization; no E2 spike, no estrogenic water bloat, no gyno risk without other AAS in the stack.
  • Cleaner on liver: False / wash. Turinabol is 17α-alkylated like dianabol; liver burden is roughly comparable per mg. Some users report mildly less ALT bump on turinabol than dianabol at equivalent doses, but the magnitude is small and obligate.
  • Cleaner on lipids: False. Turinabol is worse on HDL than dianabol because dianabol's modest aromatization to E2 partially preserves HDL; turinabol's blocked aromatization eliminates that protection. This is a counterintuitive but well-established finding among health-conscious bodybuilder bloodwork series.
  • Cleaner on strength / size: False. Dianabol is more potent per mg for strength + size gains; turinabol is the "drier, less potent" cousin.
  • Cleaner on detection: Catastrophically false. Dianabol clears in ~5-6 weeks; turinabol's M3 stays detectable 9-12+ months. Turinabol is the worst AAS for athletes who may ever be tested.

Verdict on the "cleaner than dbol" reputation: The non-aromatizing is real, and is the only meaningful axis on which turinabol is "cleaner." On lipids, detection, and overall risk profile, turinabol is worse than dianabol.

3. The East German cohort + the precautionary principle for adolescent AAS use

The Franke + Berendonk 1997 Clinical Chemistry paper (PMID 9216474), built from declassified Stasi documents released after German reunification, remains one of medicine's most important documents on long-term AAS exposure in adolescent athletes. The State Plan Topic 14.25 (Themenplan 14.25) ran from 1968-1989 and dosed approximately 10,000 East German athletes — including adolescents as young as 14-16, predominantly female swimmers, throwers, and shot putters — with turinabol daily for years, often disguised as "vitamins" or "recovery supplements" without informed consent.

Documented long-term harms in this cohort include:

  • Female athletes: irreversible voice deepening (Heidi Krieger / Andreas Krieger case is the most famous), hirsutism, clitoral hypertrophy, menstrual disruption, infertility, increased rates of ovarian cysts, breast cancer, gynecological pathology, depression
  • All athletes (M + F): liver tumors / hepatic adenomas, severe acne and dermatologic harm, cardiovascular disease at younger ages than expected, mood disorders / depression, addiction and substance abuse sequelae
  • Offspring of female athletes: elevated rates of birth defects, developmental delays, miscarriage

The precautionary case for SKIP-AT-20: Adolescents and young adults under ~25 are still completing prefrontal maturation, HPG axis maturation, and bone-mineral-density consolidation. Supraphysiologic AR activation during this window is largely understudied for cognitive endpoints but the East German cohort provides the strongest available "what happens at sustained doses for years in this age range" evidence — and the answer is "long-term physical, hormonal, oncologic, and psychiatric harm at population level." For users in this archetype at 20yo with peak natural T, the precautionary case is overwhelming.

4. "It was used by the East Germans, so it must be the optimal performance compound"

A persistent bodybuilder talking point: turinabol is "Olympic-grade" because the East German state-doping program selected it for its top athletes.

Reality: The State Plan Topic 14.25 selected turinabol for specific operational reasons that don't translate to bodybuilder use:

  1. Jenapharm produced it locally — supply chain control was paramount for a state secret program
  2. Non-aromatizing = less obvious water-driven scale gains in female athletes, slower visible virilization than testosterone
  3. Daily oral dose = easier to disguise as "vitamins" than weekly injections
  4. Strength gain without weight-class disruption = ideal for class-based sports (weight lifting, throwing, swimming where weight matters)

These are operational + concealment advantages, not "this is the best AAS" advantages. The modern bodybuilder consensus is that turinabol is roughly equivalent to oxandrolone (Anavar) in profile — moderate anabolic, dry / lean, modest strength gain, obligate liver burden. It's not magic.

5. Long-term metabolite mechanism: why M3 stores so long

The M3 metabolite is unusual in steroid pharmacology because of its lipophilicity profile combined with fat-cell storage. The 18-nor-13-ene + reduced A-ring + 17β-hydroxymethyl modifications make it sufficiently lipophilic to partition into adipose tissue, from which it is slowly released back into circulation and excreted in urine over months. This is the same general mechanism by which THC's 11-OH-THC metabolite stays detectable longer than parent THC, though the magnitude (months) is much longer for M3.

Clinical implication: Lean / low-body-fat athletes may have shorter M3 detection windows than higher-body-fat individuals. High-body-fat individuals can shed body fat post-cycle and "release" stored M3 back into circulation, sometimes producing positive tests months after they thought they were clean. This is why some MMA / boxing / fitness competitor positive tests trace back to cycles run a year or more before the test event — the cut for the fight mobilized stored M3.

6. The "5 mg / 10 mg / weeks per cycle" therapeutic vs. recreational dose disconnect

Jenapharm's clinical use was 5-10 mg/day for limited courses in catabolic indications. Recreational bodybuilder use is 20-50 mg/day for 6 weeks. The East German Topic 14.25 protocol typically used 10-30 mg/day in adult males but ran for years rather than weeks — the cumulative exposure in the East German cohort dwarfs what any modern bodybuilder cycle would produce, and that cumulative exposure is what produced the documented harm patterns.

For modern users, the cumulative-dose / cumulative-cycle question is the gating one. A single 6-week 30 mg/day cycle is ~1260 mg total exposure; the East German Krieger 1986 documented exposure was ~2600 mg in a single year, and many GDR athletes had this level of exposure for ~5-10 years. The bodybuilder "one cycle won't do anything" framing is partially true for single-cycle use but is empirically refuted for multi-year recreational patterns by the East German follow-up data.

▸ Verdict change log
  • 2026-05-10 (this file) — Initial verdict: SKIP-AT-20 HIGH confidence. Same-family logic to entire AAS cluster + two turinabol-specific aggravators: (a) M3 long-term metabolite (~9-12+ month urine detection) makes any future tested-MMA aspiration permanently disqualifying — 2016 IOC reanalyses of Beijing 2008 + London 2012 produced ~80 retroactive AAFs validating the long-detection-window science; (b) East German State Plan Topic 14.25 (~10,000 athletes 1968-1989) provides one of medicine's most explicit adolescent-AAS-harm datasets (Franke + Berendonk 1997 PMID 9216474) — virilization, liver tumors, CVD, infertility, mood disorders, offspring birth defects. The "lean dry gains" framing of turinabol does not change the underlying inappropriateness for users in this archetype-archetype at 20yo with peak natural T. Verdict reverses ONLY for documented severe catabolic medical indication under endocrinology supervision (clinically implausible + turinabol is no longer manufactured anyway).
▸ Open questions / gaps Open
  • M3 detection window upper bound at chronic-recreational dose patterns. Most published controlled-administration data uses single-dose or short-course paradigms. Real-world chronic users (multiple cycles over years) may show longer M3 detection windows than the 9-12 month upper estimate — fat-cell storage + slow release + body composition cuts can produce surprise positives. Reasonable margin for any tested aspiration: 2 years post-last-dose for pragmatic "essentially clean" framing.
  • Modern (2020s) recreational user long-term outcomes. Most clinical AAS long-term outcome data (Baggish 2017 cardiac MRI, etc.) mixes AAS classes; turinabol-specific multi-cycle outcome data is sparse compared to testosterone or trenbolone literature. Extrapolation from class effects is reasonable but turinabol-specific cardiovascular trajectory data has gaps.
  • Authentic-product question. Since Jenapharm production stopped in 1994, no legitimate manufacturer of pharmaceutical-grade turinabol exists. Modern UGL "Tbol" products carry significant authenticity risk — verifying that "turinabol" sold in 2026 is actually CDMT vs. mis-dosed or substitute compounds is a real and underappreciated problem. For users in this archetype, this reinforces SKIP (you may be running an unknown compound under a turinabol label).
  • MMA-specific testing programs and their detection-window assumptions. USADA / WADA / state combat-athletic-commission programs use varying testing windows + methods. The user's plausible future tested-MMA trajectory should assume worst-case 12-month M3 detection — but specific commission programs may use older / less sensitive methods, reducing real-world risk somewhat. Don't bet career on commission-method-gaps; assume worst case.
▸ Cross-references

Same-family AAS skip-at-20 cluster:

  • testosterone-enanthate — injectable parent compound; not 17α-alkylated → cleaner liver profile; but aromatizes → estrogenic side effects requiring AI management; SKIP-AT-20 same logic
  • dianabol / methandienone — turinabol's parent compound (turinabol = dianabol + 4-chloro); aromatizing, more potent per mg, water retention; SKIP-AT-20 same logic
  • oxandrolone / anavar — closest profile match (non-aromatizing, "dry / lean," 17α-alkylated, modest potency, FDA-approved for catabolic indications); SKIP-AT-20 same logic
  • methenolone / primobolan — DHT-derived non-aromatizing AAS with similar dry-cycle profile; injectable form less hepatotoxic; oral form 17α-alkylated; SKIP-AT-20 same logic
  • methyltestosterone — first 17α-alkylated oral AAS (1935); aromatizes, more hepatotoxic than turinabol; SKIP-PERMANENT (strictly dominated)

Adjuncts commonly stacked with turinabol (mostly NOT recommended for users in this archetype):

  • anastrozole — aromatase inhibitor; pharmacologically pointless with turinabol (non-aromatizing); included on the AAS-stack landscape map for context
  • tudca — hepatic-support adjunct; reduces 17αAA cholestatic risk modestly but does NOT make turinabol "safe"

References

Franke WW, Berendonk B — Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government, Clinical Chemistry 1997

pubmed.ncbi.nlm.nih.gov · 1997

PMID 9216474; foundational paper on East German doping cohort, built from declassified Stasi documents

View Study

Sobolevsky T, Rodchenkov G — Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine, J Steroid Biochem Mol Biol 2012

pubmed.ncbi.nlm.nih.gov · 2012

PMID 22142641; identification of M3 long-term metabolite that enabled 2016 IOC reanalyses

View Study

Schänzer W, Horning S, Opfermann G, Donike M — Gas chromatography/mass spectrometry identification of long-term excreted metabolites of the anabolic steroid 4-chloro-1,2-dehydro-17alpha-methyltestosterone in humans, J Steroid Biochem Mol Biol 1996

pubmed.ncbi.nlm.nih.gov · 1996

PMID 8639473; foundational long-term metabolite identification work preceding the M3 method

View Study

Loke S, et al. — Controlled administration of dehydrochloromethyltestosterone in humans: Urinary excretion and long-term detection of metabolites for anti-doping purpose, J Steroid Biochem Mol Biol 2021

pubmed.ncbi.nlm.nih.gov · 2021

PMID 34418529; modern controlled administration trial confirming detection at 45+ days from a single 5 mg oral dose

View Study

Schiffer L, et al. — Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes, Drug Metabolism and Disposition 2016

pubmed.ncbi.nlm.nih.gov · 2016

PMID 26658226; CYP11A1/B1/B2 + CYP3A4 metabolism mechanism work

View Study

Chlorodehydromethyltestosterone — Wikipedia

en.wikipedia.org · 1961

primary reference; pharmaceutical history (Jenapharm 1961 patent, 1965 clinical introduction, 1994 production discontinuation), structural / pharmacokinetic context, East German doping summary

View Source

Jenapharm — Wikipedia

en.wikipedia.org

corporate history of the East German pharmaceutical company that manufactured Oral-Turinabol

View Source

Doping in East Germany — Wikipedia

en.wikipedia.org · 1968

overview of State Plan Topic 14.25 (1968-1989), athlete numbers, documented harms

View Source

Andreas Krieger — Wikipedia

en.wikipedia.org · 1986

most-documented individual case from the GDR program (formerly Heidi Krieger, 1986 European shot put gold medalist)

View Source

Anabolic Steroids — LiverTox NCBI Bookshelf NBK548931

ncbi.nlm.nih.gov

class entry on AAS hepatotoxicity, including 17α-alkylated AAS profile

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…